Browsing by Author Jackson, K

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 4 to 19 of 19 < previous 
TitleAuthor(s)Issue DateViews
 
Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy [3]
Journal:Blood
Hui, CKBowden, SJackson, KAu, WYFong, DYTLie, AKWChim, CSLiang, RLau, GKK
2005
144
 
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
Journal:Journal of Hepatology
Yuen, MFLocarnini SLim, THStrasser, SISievert WCheng, WThompson, AJGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KLai, CLGish, RGGane, E
14-Oct-2022
 
Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial
Proceeding/Conference:Journal of Hepatology
Yuen, RMFElkashab, MChen, CYCoffin, CFung, SGreenbloom, SJang, JWJeng, RWJKim, DJKim, YJKim, WLee, KSLim, YSRamji, AIyer, RMacfarlane, CJackson, KLocarnini, SAfdhal, NChan, H
2018
58
 
Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2019
41
 
Effects of SB9200 (Inarigivir) therapy on immune responses in patients with chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Walsh, RHammond, RJackson, KEdwards, EMacfarlane, CIyer, RYuen, RMFChan, HAfdhal, NLocarnini, S
2018
44
 
First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA)
Proceeding/Conference:Hepatology
Yuen, RMFLocarnini, SGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GJackson, KFerrari, CLai, CLLiu, SHKMak, LYWong, DKHTo, WPKo, KLGish, RG
2019
112
 
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JLi, ZCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2018
83
 
Inarigivir demonstrates potent dose dependent anti-viral activity in HBV treatment-naive patients: role of HBeAg status and baseline HBsAg in anti-viral response
Proceeding/Conference:Hepatology
Yuen, RMFElkhashab, MChen, CYChen, YFCoffin, CSFung, SKGreenbloom, SJang, JWJeng, WJKim, DJKim, YJKim, WLee, KSLim, YSLiu, CJRamji, AIyer, RMacfarlane, CJackson, KLocarnini, SAfdhal, NHChan, HLYACHIEVE STUDY Investigators,
2018
34
 
Inarigivir: a novel RIG-I agonist for chronic hepatitis B
Proceeding/Conference:Hepatology International
Macfarlane, CLocarnini, SJackson, KWalsh, REdwards, RHammond, RCoffin, CElkhashab, MGreenbloom, SRamji, AChan, HLYAfdhal, WKim, NAfdhal, NYuen, RMFWong, DKHLyer, R
2018
88
 
Novel anti-viral activity of SB 9200, a RIGI agonist; results from Cohort 1 of the ACHIEVE trial
Proceeding/Conference:Hepatology
Locarnini, SWong, DKHJackson, KWalsh, REdwards, RHammond, RMacfarlane, CIyer, RPAfdhal, NHYuen, RMF
2017
47
 
RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLiu, SHKGiven, BSchluep, THamilton, JLai, CLLocarnini, SJackson, KLai, JYFerrari, CGish, RG.
2018
88
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2021
44
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International
Gane, ELocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AJGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont, MLenz, ORidder, FDCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RYuen, RMF
2022
 
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGGane, E
2019
73
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
78
 
Utility of a new HBV RNA assay in HBeAg positive and negative CHB and following HBsAg seroclearance in patients treated with ARC‐520, an RNAi drug targeting cccDNA derived HBV mRNA
Proceeding/Conference:Journal of Viral Hepatitis
Buter, EKWong, DKHJackson, KSchluep, TGersch, JKuhns, MCloherty, GALocarnini, SYuen, RMF
2018
52
Showing results 4 to 19 of 19 < previous